Skip to content
★ Sign in to follow
PA

Polaris AI Pharma Corp. Stock: price and insider trades · South Korea

폴라리스AI파마

KR·Mcap ₩77BTechnology

No insider purchase over the last 90 days. The latest, by 폴라리스오피스, was filed 10 Jul 2026.

Polaris AI Pharma Corp.: what insiders have been doing

Polaris AI Pharma Corp. is a Technology company. Its directors and officers file their transactions with DART (FSS). In the past year (8 November 2025 to 8 November 2026), 1 filing came from 1 insider.

Only purchases show up on the open market, 1 purchase in all, filed by 1 insider. The amount is not disclosed for 1 filing. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 major shareholder among the declarants.

The clock since the last published purchase (10 July 2026) now reads 121 days.

Across the 2,630 companies tracked on its exchange, the median is 7 filings; at 1 filing, this issuer sits below that mark. The full history, which starts in 2021, counts 6 purchases against no sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Core Scientific, Inc./tx and Gitlab Inc. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.

Insider Decl.
13
Thresholds
n/a
Buy Volume
n/a
6 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
폴라리스오피스1 buy

Since the insiders bought

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Fundamental score
Ranked 11,337 of 26,897 companies
55.6
score / 100
Value
70
Quality
41
FCF yld12%
Earn yld8.9%
EV/EBITDA12.1x
ROE·
Gross mgn22%
Net mgn11%
Debt/EBITDA5.1x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩5,800
Analyst consensus
·
Income statement
Revenue₩55.5B
Gross profit₩12.3B22% margin
EBITDA₩9.9B18% margin
Net income₩6.2B11.1% margin
Balance sheet & cash
Market cap₩77B
Total debt₩50.8B
Free Cash Flow₩8.3B
Last declaration on 10 July 2026
Declarations14 total
  • Other
    Other(filed)
    0DART
  • ▲
    대량보유자Executives(filed)
    0DART
    186,843 sharesKRXDART:20260710000694
    Canonical exit: 8 Oct 2026 (T+90)
  • ▲
    Executives
    0DART
    227,918 sharesKRXDART:20241008000549
    Canonical exit: 29 Dec 2024 (T+90)
  • ▲
    Executives
    0DART
    800,000 sharesKRXDART:20240603000335
    Canonical exit: 30 Aug 2024 (T+90)
  • ▲
    Executives
    0DART
    575,426 sharesKRXDART:20240521000338
    Canonical exit: 14 Aug 2024 (T+90)
  • ▲
    Executives
    0DART
    3,000 sharesShareKRXDART:20240411003883
    Canonical exit: 2 Jul 2024 (T+90)
  • ▲
    Executives
    0DART
    1,000 sharesShareKRXDART:20230921000146
    Canonical exit: 19 Dec 2023 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART

14 of 14 declarations

About Polaris AI Pharma Corp.

Polaris AI Pharma is a technology company listed on the XKRX market. It specializes in developing artificial intelligence solutions for the pharmaceutical industry.